Glioblastoma is one of the most malignant brain tumors. Current treatments for glioblastoma usually make poor responses, and novel treatment strategies are extremely imperative. Cytochalasin E was reported to inhibit angiogenesis and tumor growth in some studies, but its effects on gliomas are still unknown. In this study, we found cytochalasin E inhibits U87 human glioblastoma cell growth in a very low concentration range of 10^-8 to 10^-6 M in a time and concentration dependent manner, and the IC50 were 1.17 ± 0.32 × 10^-7 M for 48 h treatment, 6.65 ± 1.12 × 10^-8 M for 72 h and 3.78 ± 1.30 × 10^-8 M for 96 h. We also found cytochalasin E induces cell-cycle G2/M phase arrest (72 h-treatment of 10^-6 M cytochalasin E caused 56.2 ± 6.1 % cells arrest in G2/M phase) and cell apoptosis (96 h-treatment of 10^-6 M cytochalasin E induced 24.1 ± 4.2 % cells apoptosis). Thus, cytochalasin E is proposed as a potential agent for glioblastoma chemotherapy.Colegio de Farmacéuticos de la Provincia de Buenos Aires